Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor

References

• Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation103, 1838–1843 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Int. Med.163, 1849–1856 (2003).
   PubMed Web of Science ®Google Scholar
• LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med.32, 976–980 (2004).
   PubMed Web of Science ®Google Scholar
• Reddy BV, Grossman EJ, Nahlik L, Trevino S, Murray PT. Argatroban anticoagulation during renal replacement therapy in patients with heparin-induced thrombocytopenia. J. Am. Soc. Nephrol.13, 604a (2004).
   Google Scholar
• Tang I, Cox DS, Patel K et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann. Pharmacother. (2004) (In Press).
   Google Scholar
• Matthai WH, Lewis BE, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb. Res. (2004) (In Press).
   PubMedGoogle Scholar
• Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet. Cardiovasc. Interven.57, 177–184 (2002).
   PubMed Web of Science ®Google Scholar
• Kobayashi W, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Sem. Thromb. Hemost.23, 531–534 (1997).
   PubMed Web of Science ®Google Scholar
• Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: a multicenter clinical trial of argatroban. J. Thromb. Thrombol.2, 131–136 (1995).
   PubMedGoogle Scholar
• Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol. Dial. Transplant.18, 1623–1630 (2003).
   PubMed Web of Science ®Google Scholar
• LaMonte MP, Nash ML, Wang DZ et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke35, 1677–1682 (2004).
   PubMed Web of Science ®Google Scholar
• Herrman J-P, Suryapranata H, den Heijer P, Gabriël L, Kutryk MJB, Serruys PW. Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J. Thromb. Thrombol.3, 367–375 (1996).
   PubMedGoogle Scholar
• Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J. Thromb. Thrombol.18, 31–37 (2004).
   PubMed Web of Science ®Google Scholar
• Murray PM, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int.66, 2446–2453 (2004).
   PubMed Web of Science ®Google Scholar
• Jang IK, Brown DFM, Giugliao RP et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) trial. J. Am. Coll. Cardiol.33, 1879–1885 (1999).
   PubMed Web of Science ®Google Scholar
• Vermeer F, Vahanian A, Fels PW et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J. Thromb. Thrombol.10, 233–240 (2000).
   PubMed Web of Science ®Google Scholar
• Kathiresan S, Shiomura J, Jang IK. Argatroban. J. Thromb. Thrombol.13, 41–47 (2002).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch. Int. Med.164, 361–369 (2004).
   PubMedGoogle Scholar
• Alsoufi B, Boshkov LK, Kirby A et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Ann.7, 155–171 (2004).
   PubMedGoogle Scholar
• Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood101, 31–37 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest126, S311–S337 (2004).
   Google Scholar
• Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood96, 1703–1708 (2000).
   PubMed Web of Science ®Google Scholar
• Shuster TA, Silliman WR, Coats RD, Mureebe L, Silver D. Heparin-induced thrombocytopenia: 29 years later. J. Vasc. Surg.38, 1316–1322 (2003).
   PubMed Web of Science ®Google Scholar
• Campbell KR, Mahaffey KW, Lewis BE et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J. Invas. Cardiol.12(Suppl. F), F14–F19 (2000).
   PubMedGoogle Scholar
• Warkentin TE. Heparin-induced thrombocytopenia: a 10-year retrospective. Ann. Rev. Med.50, 129–147 (1999).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med.343, 1286–1292 (2001).
   Google Scholar
• Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann. Intern. Med.136, 210–215 (2002).
   PubMed Web of Science ®Google Scholar
• Levine RL, Hursting MJ, Drexler A et al. Heparin-induced thrombocytopenia in the emergency department. Ann. Emer. Med.44, 511–515 (2004).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med.127, 804–812 (1997).
   PubMed Web of Science ®Google Scholar
• Srinivasan AF, Rice L, Bartholomew JR et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch. Int. Med.164, 66–70 (2004).
   PubMed Web of Science ®Google Scholar
• Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb. Hemost.70, 554–561 (1993).
   PubMed Web of Science ®Google Scholar
• Kodityal S, Manhas AH, Udden M, Rice L. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur. J. Hematol.71, 109–113 (2003).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Koza MJ, Lewis BE, Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thromb. Hemost.2(Suppl. 1), S21–S27 (1996).
   Web of Science ®Google Scholar
• Greinacher A, Völpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation99, 73–80 (1999).
   PubMed Web of Science ®Google Scholar
• Fischer KG. Hirudin in renal insufficiency. Semin. Thromb. Hemost.28, 467–482 (2002).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation108, 2062–2065 (2003).
   PubMed Web of Science ®Google Scholar
• Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart J.142, 952–959 (2001).
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Lewis BE, Wildermann NM et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J. Invas. Cardiol.15, 611–616 (2003).
   PubMedGoogle Scholar
• Ingall T. Stroke-incidence, mortality, morbidity and risk. J. Insur. Med.36, 143–152 (2004).
   PubMedGoogle Scholar
• The National Institute of Neurological Disorders, and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med.333, 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• Adams HP, Adams RJ, Brott T et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke34, 1056–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb. Hemost.72, 381–386 (1994).
   PubMed Web of Science ®Google Scholar
• Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban’s inhibition of thrombin. Blood92, 2064–2074 (1998).
   PubMed Web of Science ®Google Scholar
• Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time. Br. J. Pharmacol.113, 1209–1214 (1994).
   PubMed Web of Science ®Google Scholar
• Kawai H, Umemura K, Nakashima M. Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J. Pharmacol.69, 143–148 (1995).
   PubMedGoogle Scholar
• Kawai H, Yuki S, Sugimoto J, Tamao Y. Effects of a thrombin inhibition, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther.278, 780–785 (1996).
   PubMed Web of Science ®Google Scholar
• Morris DC, Zhang L, Zhang ZG et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke32, 2635–2640 (2001).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Alford KL, Becker JC et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Hemostas.23, 503–516 (1997).
   PubMed Web of Science ®Google Scholar
• Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy20, 318–329 (2000).
   PubMed Web of Science ®Google Scholar
• Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy20, 756–770 (2000).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Fasanella AR, Iqbal O et al. Coagulation laboratory testing in patients treated with argatroban. Semin. Thromb. Hemost.25(Suppl. 1), 61–66 (1999)
   PubMedGoogle Scholar
• Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin. Chem.45, 409–412 (1999).
   PubMed Web of Science ®Google Scholar
• Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Hemost.85, 435–440 (2001).
   PubMed Web of Science ®Google Scholar
• Harder S, Graff J, Klinkhardt U et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb. Hemost.91, 1137–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Cox DS, Kleiman NS, Boyle DA et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention. J. Clin. Pharmacol.44, 981–990 (2004)
   PubMed Web of Science ®Google Scholar
• Clark RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation83, 1510–1518 (1991).
   PubMed Web of Science ®Google Scholar
• Tran JQ, DiCicco RA, Sheth SB et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J. Clin. Pharmacol.39, 513–519 (1999).
   PubMed Web of Science ®Google Scholar
• Inglis AML, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco R. Investigation of the interaction between argatroban and acetaminophen, lidocaine or digoxin. Am. J. Health Syst. Pharm.59, 1258–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Brown PM, Hursting MJ. Lack of pharmacokinetic interactions between argatroban and warfarin. Am. J. Health Syst. Pharm.59, 2078–2083 (2002).
   PubMed Web of Science ®Google Scholar
• Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am. J. Health Syst. Pharm.59, 1784–1785 (2002).
   PubMed Web of Science ®Google Scholar
• Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with select cardiovascular agents. Am. J. Health Syst. Pharm.61, 2415–2418 (2004).
   Google Scholar
• Patel K, Hursting MJ. Compatibility of argatroban and glycoprotein IIb/IIIa receptor antagonists during simulated Y-site administration. Am. J. Health Sys. Pharm. (2005) (In Press).
   Google Scholar
• Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann. Pharmacother.37, 970–975 (2003).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Jeske WP, Wallis DE et al. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin. Thromb. Hemost.25(Suppl. 1), 77–81 (1999).
   PubMedGoogle Scholar
• O’Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin. Dial.16, 61–67 (2003).
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamada T, Yamanshi T, Ryo R. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia. Thromb. Res.58, 663–666 (1990).
   PubMed Web of Science ®Google Scholar
• Koide M, Yamamoto S, Matsuo M, Suzuki S, Arima N, Matsuo T. Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol. Dial. Transplant.10, 2137–2140 (1995).
   PubMed Web of Science ®Google Scholar
• Lewis BE, Grassman ED, Wrona L, Rangel Y. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coag. Fibrinol.8, 54–58 (1997).
   PubMed Web of Science ®Google Scholar
• Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology49, 61–67 (1998).
   PubMed Web of Science ®Google Scholar
• Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol. Oncol. Clin. North Am.14, 445–457 (2000).
   PubMed Web of Science ®Google Scholar
• Johnston N, Wait M, Huber L. Argatroban in adult extracorporeal membrane oxygenation. J. Am. Soc. Extra Corp. Technol.34, 281–284 (2002).
   PubMedGoogle Scholar
• LaMonte MP, Stallmeyer MJ. Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study. J. Thromb. Thrombol.17, 151–156 (2004).
   PubMed Web of Science ®Google Scholar
• Arnoletti JP, Whitman GJR. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann. Thorac. Surg.68, 576–578 (1999).
   PubMed Web of Science ®Google Scholar
• Ide H, Fujiki T, Sato M, Endo H, Imamura K, Sudo K. Off-pump coronary artery bypass for a heparin-allergic patient. Jpn J. Thorac. Cardiovasc. Surg.49, 250–254 (2001).
   PubMedGoogle Scholar
• Kieta DR, McCammon AT, Holman WL, Nielson VG. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth. Analg.96, 956–958 (2003).
   PubMed Web of Science ®Google Scholar
• Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessels18, 40–42 (2003).
   PubMed Web of Science ®Google Scholar
• Kamei M, Miyata S, Niwaya K et al. Successful argatroban anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia Type II. J. Thromb. Hemost.1(Suppl. 1), P1162 (2003).
   Google Scholar
• Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann. Thorac. Surg.75, 1622–1624 (2003).
   PubMed Web of Science ®Google Scholar
• Tokuda Y, Matsumoto M, Sugita T et al. Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia. Circ. J.67, 889–890 (2003).
   PubMed Web of Science ®Google Scholar
• Cannon MA, Butterworth J, Riley RD, Hyland JM. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann. Thorac. Surg.77, 711–713 (2004).
   PubMed Web of Science ®Google Scholar
• Liedel JL, Panicker N, Kahana MD. Argatroban for anticoagulation in children with heparin-induced platelet antibodies. Crit. Care Med.31(Suppl.), A132 (2003).
   Google Scholar
• Cetta F, Graham LC, Wrona LL, Arruda MJ, Walenga JM. Argatroban use during pediatric interventional cardiac catheterization. Cath. Cardiovasc. Interv.61, 147–149 (2004).
   PubMed Web of Science ®Google Scholar
• Albers GW, Amerenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest119, S300–S320 (2001).
   Google Scholar
• The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled study. J. Am. Med. Assoc.279, 1265–1272 (1998).
   PubMed Web of Science ®Google Scholar
• Malherbe S, Tsui BC, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated Factor VII. Anesthesiology100, 443–445 (2004).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin. Appl. Thromb. Hemostas. (2004) (In press).
   Google Scholar
• Lewis BE, Wallis DE, Zehnder JL, Barton JC. Argatroban reexposure in patients with heparin-induced thrombocytopenia. Blood96(Pt 1), 52a (2000).
   Google Scholar
• Walenga JM, Ahmad S, Hoppensteadt DA, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb. Res.106(2), 401–405 (2002).
   Google Scholar
• Kelton JG, Hursting MJ, Lewis BE. The predictors of clinical outcome in patients with heparin-induced thrombocytopenia. J. Thromb. Hemost.1(Suppl. 1), OC020 (2003).
   Google Scholar
• Kruse KR, Crowley JJ, Tanguay JF et al. Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model. Catheter Cardiovasc. Intervent.46, 503–507 (1999).
   PubMedGoogle Scholar
• Itoh T, Nonogi H, Miyasaki S et al. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: a prospective randomized pilot study. Circ. J.68, 615–622 (2004).
   PubMed Web of Science ®Google Scholar
• Berry CN, Lunven C, Lecoffre C et al. Anticoagulant activity and pharmacokinetic properties of a subcutaneously administered mixed micellar formulation of argatroban in experimental animals. Thromb. Hemost.84, 278–285 (2000).
   PubMed Web of Science ®Google Scholar
• Berry CN, Visconte C, Lecoffre C, Lochot S, Girard D. Activity of a subcutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis. Thromb. Hemost.84, 286–290 (2000).
   PubMed Web of Science ®Google Scholar
• Williams RT, Damaraju LV, Mascelli MA et al. Antiplatelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation107, 2307–2312 (2003).
   PubMed Web of Science ®Google Scholar
• Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital. Heart J.1, 39–42 (2000).
   PubMedGoogle Scholar